Skip to main content

Table 1 Descriptive characteristics of patients

From: Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series

Patient Diagnosis TNF-α inhibitor DMARD Age in years, BMI Sex, race Episodes of low glucose readings Venous glucose value, mg/dL Total duration on TNF-α inhibitor Time before development of hypoglycemia History of diabetes? Family history of diabetes? History of gestational diabetes?
1 RA Infliximab, etanercept Hydroxychloroquine 68, 22.0 Female, Caucasian 2 67, 68 13 months
(infliximab),
10 months
(abatacept)
6 months, 10 months No No No
2 RA, SLE, CREST syndrome Infliximab Hydroxychloroquine,
MTX
54, 32.4 Female, Caucasian 1 66 13 months
(infliximab)
8 months No Yes No
3 RA Infliximab Leflunomide 62, 22.1 Female, Caucasian 1 60 24 months (infliximab) 4 months No No No
4 RA, SpA Adalimumab Hydroxychloroquine 29, 18.3 Female, Caucasian 1 67 3 months
(adalimumab)
3 months No No No
5 RA, FMS Certolizumab, infliximab Leflunomide 35, 19.3 Female, Caucasian 2 69, 63 11 months
(abatacept),
14 months
(infliximab)
2 months,
3 months
No No No
6 RA, SLE, CREST syndrome Adalimumab, certolizumab, infliximab Leflunomide 55, 24.5 Female, Caucasian 4 63, 62, 62, 68 17 months (adalimumab),
17 months
(certolizumab)
4 months, 14 months, 15 months, 6 months No No No
7 RA, vWD Adalimumab, golimumab MTX 30, 19.6 Female, Caucasian 3 68, 58 11 months
(adalimumab),
3 months
(golimumab)
6 months, 1 month No No No
8 RA, SpA, FMS Adalimumab None 47, 21.4 Female, Caucasian 1 54 11 months (adalimumab) 2 months No No No
9 RA, FMS Infliximab Hydroxychloroquine 65, 19.8 Female, Caucasian 1 64 24 months (infliximab) 5 months No No No
  1. BMI: body mass index; CREST: calcinosis, Raynaud syndrome, esophageal dysmotility, sclerodactyly, and telangiectasia; DMARD: disease-modifying anti-rheumatoid drug; FMS: fibromyalgia syndrome; MTX: methotrexate; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SpA: spondyloarthropathy; TNF-α: tumor necrosis factor-alpha; vWD: von Willebrand disease.